Codexis, Inc. (NASDAQ:CDXS) Director Byron L. Dorgan sold 16,702 shares of Codexis stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $14.02, for a total value of $234,162.04. Following the completion of the sale, the director now directly owns 153,838 shares in the company, valued at approximately $2,156,808.76. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
NASDAQ CDXS opened at $13.27 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 7.37 and a quick ratio of 7.34. The business’s 50 day moving average price is $15.95 and its 200-day moving average price is $14.94. Codexis, Inc. has a fifty-two week low of $12.46 and a fifty-two week high of $22.38.
A number of research firms have issued reports on CDXS. HC Wainwright reaffirmed a “buy” rating and issued a $22.50 price objective on shares of Codexis in a research note on Tuesday, December 24th. Zacks Investment Research downgraded Codexis from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. BidaskClub downgraded Codexis from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 13th. Finally, ValuEngine raised Codexis from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 31st.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Featured Story: S&P/ASX 200 Index
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.